Moderna Inc. ($MRNA) Stock Forecast: Up 12.6% Today

What is Moderna Inc.?

Moderna, Inc. (MRNA) is a biotechnology company that is recognized for its groundbreaking mRNA technology, notably utilized in the development of COVID-19 vaccines. The company's focus has expanded to include the advancement of treatments for cancer and rare diseases.

Why is Moderna Inc. going up?

MRNA stock is up 12.6% on Jun 30, 2026 13:51

• The positive outlook on Moderna's mRNA technology extending beyond vaccines, particularly in cancer and rare disease therapies, likely influenced its upward movement today.
• Moderna's strong performance compared to other companies in the therapeutics sector, as seen in the Q1 earnings review, may have bolstered investor confidence.
• The increased awareness of Moderna's diversified pipeline and growth potential across various healthcare sectors could have attracted more investors, leading to its upward movement.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

ETFs Investing in Moderna, Inc. Stocks

This article lists various ETFs that include Moderna, Inc. (MRNA) stocks in their holdings. The ETFs are sorted by market value and provide details such as weight of MRNA, issuer, management style, expense ratio, and assets under management. The aim is to help investors find accessible investment opportunities with lower risk through ETFs holding MRNA.

https://www.tradingview.com/symbols/BMV-MRNA/etfs/

Therapeutics Stocks Q1 Recap: Benchmarking Vertex Pharmaceuticals (NASDAQ:VRTX)

This article provides a Q1 earnings recap for therapeutics stocks, focusing on Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers. It highlights the strong start for Vertex, driven by its leadership in cystic fibrosis and growth in other areas, despite delivering the weakest full-year guidance update. The report also benchmarks other companies like Moderna (NASDAQ:MRNA) as the best performer and United Therapeutics (NASDAQ:UTHR) as the weakest in Q1, offering insights into their financial results and market reactions.

https://www.theglobeandmail.com/investing/markets/stocks/VRTX/pressreleases/3051124/therapeutics-stocks-q1-recap-benchmarking-vertex-pharmaceuticals-nasdaqvrtx/

AbbVie Climbs to 52-Week High: Is the Pharma Giant Still Worth Buying?

AbbVie Inc. (NYSE: ABBV) recently reached a 52-week high, buoyed by its $10.9 billion acquisition of Apogee Therapeutics (NASDAQ: APGE). Despite the rally, the pharmaceutical giant trades at a discount to the S&P 500 and offers a strong dividend yield. While the Apogee deal extends AbbVie's immunology pipeline, the long payoff timeline and inherent clinical risks warrant caution for short-term investors, though the core thesis remains strong for long-term holders.

https://nai500.com/blog/2026/06/abbvie-climbs-to-52-week-high-is-the-pharma-giant-still-worth-buying/

Uber Stock And The Growth Rate That Matters Most

Uber's revenue growth rate has significantly slowed to 18.3% over the last twelve months, less than half its five-year compound annual rate of 37.8%. This shift from hyper-growth to a more mature expansion phase challenges the premium valuation traditionally given to Uber stock. Investors are now questioning whether current initiatives can re-accelerate growth, or if a lower growth trajectory will lead to sustained pressure on its stock multiple.

https://www.trefis.com/stock/uber/articles/604950/uber-stock-and-the-growth-rate-that-matters-most/2026-06-29

Moderna Is Applying MRNA Technology in Vaccines, but Also Cancer and Rare Disease Therapies

Moderna's mRNA technology, initially recognized for its COVID-19 vaccine success, is now being developed for therapies beyond vaccines, specifically in cancer and rare diseases. Despite the innovative technology, Morningstar analysts currently do not believe Moderna has secured a narrow economic moat due to the dynamic nature of the vaccine market. The company's future value is increasingly tied to the performance of its oncology pipeline, particularly its therapy Intismeran.

https://www.morningstar.com/company-reports/1486137-moderna-is-applying-mrna-technology-in-vaccines-but-also-cancer-and-rare-disease-therapies

Trending Today

MicroVision Inc. ($MVIS) Stock Forecast: Down 6.7% Today

fuboTV Inc. ($FUBO) Stock Forecast: Up 20.1% Today

Paysafe Limited ($PSFE) Stock Forecast: Up 9.7% Today

Prime Medicine ($PRME) Stock Forecast: Up 8.4% Today

Amplitude Inc. ($AMPL) Stock Forecast: Up 5.8% Today

Digital Turbine, Inc. ($APPS) Stock Forecast: Up 9.0% Today

Teladoc Health Inc. ($TDOC) Stock Forecast: Up 5.4% Today

FuelCell Energy ($FCEL) Stock Forecast: Up 8.0% Today

AMC Entertainment Holdings Inc. Class A ($AMC) Stock Forecast: Up 13.1% Today

Lucid Motors Inc. ($LCID) Stock Forecast: Up 13.5% Today

Moderna Inc. Price History

26.05.2026 - MRNA Stock was up 13.9%

• The positive movement in Moderna's stock is driven by the FDA advisory committee's backing of its flu vaccine, fostering confidence among investors regarding the company's future.
• Robust revenue growth in Q1 further reinforces Moderna's market position and demonstrates its ability to meet its financial targets.
• Despite the significant surge and gains so far this year, analysts on Wall Street are exercising caution, with price targets below current trading levels, hinting at possible concerns of overvaluation.
• Analysts making adjustments to price targets and maintaining "Hold" recommendations reflect varied sentiments in the market, underscoring the importance for investors to evaluate Moderna's valuation and growth potential diligently before making any investment choices.

26.05.2026 - MRNA Stock was up 11.9%

• Moderna's stock surged over 14% today, reaching $68.23, driven by positive developments in its mRNA therapeutic pipeline, particularly the FDA advisory committee's endorsement of its flu vaccine, mFLUSIVA.
• The company's strategic restructuring into three commercial franchises and plans for manufacturing investment in Germany showcased its evolution beyond COVID-19, attracting momentum traders and boosting investor confidence.
• Despite the strong performance, concerns linger around the company's profitability challenges, as indicated by its GF Score™ of 58/100 and notable insider selling activity, warranting caution among Wall Street analysts despite the stock's impressive run.
• Moderna's outperformance compared to other vaccine stocks like Merck and Pfizer today underscores the market's positive reception of its pipeline news and revenue growth, positioning the company as a diversified mRNA platform player with promising prospects.

26.05.2026 - MRNA Stock was up 5.4%

• Moderna is strategically focusing on expanding its pipeline with new therapeutic modalities and commercial products as part of its plan to break even by 2028. This forward-looking strategy has positively influenced investor sentiment and the stock's performance.
• An adjustment of Moderna's price target by analysts at Jefferies indicates confidence in the company's future prospects, especially following a positive FDA panel recommendation regarding its mRNA-based influenza vaccine. This optimism likely contributed to the stock's bullish movement.
• The impending FDA approval of Moderna's mRNA-1010 flu vaccine has been a key driver of the stock's recent gains. Despite doubling in value this year, the company's promising pipeline, which includes a personalized cancer vaccine and an HIV vaccine, continues to attract investors.
• While financial metrics remain important, market interest in Moderna seems to be centered on its innovative capabilities, upcoming catalysts, and strategic growth initiatives, all of which have propelled the stock to new heights.

18.05.2026 - MRNA Stock was up 5.5%

• Moderna's bullish movement today could be attributed to the company considering acquiring BioNTech's German manufacturing plants. This strategic move not only expands Moderna's production capacity but also positions it favorably in the European market.
• Additionally, the FDA clearance for Beam Therapeutics' BEAM-304 PKU gene-editing trial may have indirectly boosted Moderna's stock, as it highlights the advancements in genetic therapies within the biotech sector.
• The FDA scrutiny of Moderna's mRNA flu vaccine could have also impacted the stock positively, as it demonstrates the company's commitment to expanding its vaccine portfolio beyond COVID-19 solutions.
• Overall, Moderna's proactive approach towards acquisitions, clinical trials, and vaccine development seems to have resonated well with investors, driving the bullish movement in its stock price today.

18.05.2026 - MRNA Stock was up 8.0%

• Moderna's bullish movement can be attributed to the positive news surrounding its mRNA flu vaccine facing FDA scrutiny for approval in older adults. This potential approval would mark a significant milestone for the company, especially in the competitive flu vaccine market.
• The anticipation of Moderna entering the flu vaccine market with its mRNA technology, competing with traditional vaccine companies like Sanofi and GSK, has likely sparked investor optimism and contributed to the bullish trend.
• Investors may view Moderna's innovative approach to vaccine development and its potential expansion into new markets as a positive sign for the company's growth prospects, driving the stock price higher.
• The news of Moderna's mRNA flu vaccine progress overshadowed other headlines in the biotechnology sector, keeping the focus on the company's promising developments and future potential.

23.05.2026 - MRNA Stock was up 6.5%

• Following a positive outcome from an FDA advisory committee vote on the benefit-risk profile of their seasonal flu vaccine, mRNA-1010, Moderna's stock witnessed a significant rise. This development has bolstered investor confidence in the company's vaccine portfolio.
• The market's response to Moderna's recent announcement contrasts with another company's stock decline, emphasizing the importance of regulatory approvals and product advancements in shaping stock performance.
• Moderna's stock upsurge mirrors investors' confidence in its growth potential, driven by its mRNA technology and upcoming product launches. It signifies a strong market belief in Moderna's capacity to provide innovative healthcare solutions.

29.05.2026 - MRNA Stock was up 12.6%

• Moderna's stock surged almost 13% to hit a 52-week high as the company revealed its strategies to expand beyond vaccines and venture into broader biotechnology avenues. This move, which includes utilizing its mRNA platform for diverse therapies and incorporating AI for drug discovery, excited investors and led to a rise in the stock price.
• Anticipation surrounding the FDA's upcoming decision regarding Moderna's mRNA flu shot further fueled positive market sentiment. Analysts hurried to revise their price targets as the stock exceeded many of their previous estimates.
• Patton Fund Management Inc. notably increased its position in Moderna, Inc., indicating a growing faith in the company's future prospects and contributing to the stock's bullish trend.
• Market reactions indicate optimism towards Moderna's growth initiatives and the potential applications of its mRNA technology across various therapeutic fields, demonstrating investor trust in the company's long-term trajectory.

30.05.2026 - MRNA Stock was up 12.6%

• The positive outlook on Moderna's mRNA technology extending beyond vaccines, particularly in cancer and rare disease therapies, likely influenced its upward movement today.
• Moderna's strong performance compared to other companies in the therapeutics sector, as seen in the Q1 earnings review, may have bolstered investor confidence.
• The increased awareness of Moderna's diversified pipeline and growth potential across various healthcare sectors could have attracted more investors, leading to its upward movement.

29.05.2026 - MRNA Stock was up 12.6%

• Moderna's stock saw a robust surge exceeding 12% today, outpacing the majority of analyst price targets, as investor attention gravitates towards the company's diverse mRNA initiatives aside from COVID-19.
• The pending FDA decision on Moderna's mRNA flu shot, set for August 5th, stands out as a significant catalyst propelling the stock's upward trajectory.
• Despite analysts upholding a prevailing "Reduce" consensus rating, recent favorable developments surrounding Moderna's expanded portfolio encompassing oncology and autoimmune disorders are prompting a reassessment among investors.
• Moderna's strategic pivot towards the advancement of mRNA therapeutics targeting cancer, autoimmune conditions, and integration of AI-driven research initiatives is instilling a sense of optimism and bolstering investor confidence in the company's future growth prospects.

29.05.2026 - MRNA Stock was up 12.6%

• Moderna's stock saw a surge of over 12% today, surpassing most analyst price targets. This increase can be attributed to the growing investor interest in the company's various mRNA programs extending beyond COVID-19 vaccines.
• The impending FDA decision scheduled for August 5th regarding Moderna’s mRNA flu shot is a pivotal point that has prompted investors to reassess the company's stock. This reassessment follows positive updates related to Moderna's pipeline expansion in fields such as oncology and autoimmune diseases.
• The appointment of Srishti Gupta as the new CEO of NovaBridge Biosciences, along with encouraging outcomes from HCA Healthcare's gene-editing therapy study, likely influenced the optimistic mood within the biotech sector, consequently benefiting Moderna.
• Despite the notable uptrend in the stock, there are apprehensions regarding its valuation, with concerns arising about potential overvaluation due to the rapid surge and upcoming regulatory events, urging investors to exercise caution.

22.05.2026 - MRNA Stock was down 5.2%

• Confirmation of Moderna's mRNA flu vaccine, mRNA-1010, passing the FDA Advisory Committee meeting is viewed positively, notwithstanding concerns about weak operational performance and high valuation.
• Leerink Partners' adjustment of the price target and maintenance of an "Underperform" rating are seen as contributing to the prevailing negative sentiment.
• Despite a recent 6-day streak of gains and a significant increase in market capitalization, worries regarding the company's financial health and valuation being deemed "Very Unattractive" may have overshadowed any positive trend.
• The $2.25 billion settlement with Roivant Sciences could have adversely affected Moderna's stock, despite providing legal clarity, as investors might be wary of its implications on Moderna's finances and future prospects.

25.05.2026 - MRNA Stock was down 5.5%

• Today's bearish movement for Moderna could be due to profit-taking by investors following the company's Science Day event, where advancements in its mRNA pipeline were showcased without any major breakthroughs or immediate revenue-generating milestones being announced.
• The market's negative reaction may stem from the absence of near-term commercial growth catalysts, as Moderna highlighted a long-term innovation strategy across multiple therapeutic areas like cancer and autoimmune diseases.
• Investor caution might be influenced by the high expectations set by Moderna in diversifying its pipeline and expanding its mRNA platform. This caution has led to a sell-off as investors await more concrete clinical data and revenue projections.